INTRODUCTION

1
Anthrax is a highly lethal infectious disease caused by the spore-forming bacterium 2 Bacillus anthracis (24) . After entering the host, anthrax spores are rapidly exposed and 3 phagocytosed by antigen-presenting cells (APCs), such as macrophages and dendritic cells 4 (DCs), and carried to regional lymph nodes (25, 27) . Normally, at this stage, APCs act as the 5 first line of defense against microbial pathogens by engulfing and killing infectious agents. In 6 addition to macrophages, immature DCs have then reported to capture anthrax spores by 7 phagocytosis and migrate to lymphoid organs, and the lymph nodes, where they liaise with 8 and activate antigen-specific T cells (2) . They both produce numerous modulators of the 9 inflammatory response to recruit and activate additional cells of the immune system, which 10 link to the adaptive immune response (5) . During this process, however, anthrax spores are 11 able to survive, germinate into vegetative bacilli, multiply, and escape the control of the 12 innate immune system (25, 27) . The vegetative form of B. anthracis then penetrates into the 13 circulatory system by disrupting these cells, secretes high levels of exotoxin, and spreads 14 systemically, reaching 10 8 organisms per millilitre of blood (20, 25, 27, 39) . Because APCs 15 are used to bypass the host immune system in B. anthracis infection, it is important to define 16 the interactions between APCs and spore as well as the virulence factors of B. anthracis. 17 The major virulence factor of B. anthracis, exotoxin, is composed of three distinct 18 proteins -protective antigen (PA), edema factor (EF), and lethal factor (LF) -which are 19 secreted separately as non-toxic monomers (24) . The binding of LF or EF to PA results in the 20 formation of active lethal toxin (LT) or edema toxin, respectively (24) . LF is a 21 metalloprotease that cleaves most isoforms of mitogen-activated protein kinase kinase 22 (MAPKK) (15) and EF is a calmodulin-dependent adenylate cyclase that causes a prolonged 23 increase of cytosolic cyclic adenosine monophosphate (22, 31) . B. anthracis contains another 24 virulence factor, the capsule, which is composed of PGA (24 Mouse FITC-conjugated anti-IgG2a was used as isotypic control. After washing in PBS three times, the stained cells were fixed with 1% paraformaldehyde in PBS until subjected to flow 1 cytometric analysis using a FC500 flow cytometer (Beckman Coulter, Krefeld, Germany).
2
(Supplemental material). grown in E broth medium (35) . PGA was purified from cell culture supernatant as described 6 (35) . In brief, the highly viscous bacterial culture was centrifuged at 4°C (6,500 × g, 20min) licheniformis (>500 kDa), direct addition of isolated PGA to THP-1 cell or hMoDC cultures 14 would result in increase of viscosity, which might be undesirable for determining immune 15 responses. Therefore, PGA was degraded to molecular sizes ranging from 15 to 30 kDa (30 16 kDa PGA) by using acid hydrolysis. Fragmented PGA was verified by 1 H NMR spectroscopy 17 to be 99% pure (data not shown).
18
B. anthracis H9401 is a clinical isolate from a Korean cutaneous anthrax patient (37) 19 and grown in brain-heart infusion (BHI) medium (Difco, Laboratories, Detroit, MI, USA). B.
20
anthracis H9401 is fully virulent and possesses both pXO1 and pXO2 plasmids. For the 21 purification of PGA, pXO1 of B. anthracis H9401 was cured as described (14) . Western blot. To produce cell lysates, the cell pellet was resuspended in 100 µl 1× lysis 16 buffer (Sigma-Aldrich) supplemented with protease inhibitor mixture (Sigma-Aldrich) and
RESULTS
2
PGA induces specifically IL-1β β β β production in differentiated THP-1 cells and hMoDCs. this moment increased production of IL-1β in a dose-dependent manner ( Fig. 1A and B) . The (Fig. 1A) . Similarly, the extracellular IL-1β level from THP-1 cells treated with 16 PGA from B. licheniformis 9945a was an average of 4.2-fold greater than the baseline level 17 ( Fig. 1B) . 18 To test ex vivo relevance of the IL-1β production by PGA treatment in DCs, we studied 19 the effect of PGA on IL-1β production in hMoDCs. Similarly, the treatment of hMoDCs with 20 various concentrations (0, 10, 20, 40, 80, 100 µg/ml) of PGA for either 24h or 48 h also 21 increased production of IL-1β in a dose-dependent manner ( Fig. 2A and B) . The extracellular 22 IL-1β level from hMoDCs treated with PGA from B. anthracis was an average of 10.5-fold 23 greater than the baseline level at the concentration of 100 µg/ml after 48h treatment ( Fig. 2A) .
Similarly, the extracellular IL-1β level from hMoDCs treated with PGA from B. licheniformis 1 9945a was an average of 12.5-fold greater than the baseline level (Fig. 2B ). proform and extracellular release of its active form (36) . To further investigate the effect of 10 PGA on IL-1β regulation, the effect on IL-1β processing by PGA was studied by Western blot 11 analysis. A commercial antibody that detects the cleaved form of IL-1β (17 kDa) was used for 12 Western blotting, with β-actin as a control. The level of cleaved IL-1β (17 kDa) started to 13 increase 2~3 h after PGA treatment in differentiated THP-1 cells (Fig. 3A and B) and 14 hMoDCs ( Fig. 4A and B) . These findings indicate that PGA increases the processing of the 15 IL-1β proform both in vitro and ex vivo. 16 ICE is an enzyme that proteolytically cleaves precursor forms of the pro-inflammatory 17 cytokines such as IL-1β and IL-18 into active mature peptides (8) . The resulting cleavage 18 products of IL-1β and IL-18 are then available for secretion in their active forms. ICE itself 19 also exists as a proform (p45), and upon activation, the proform of ICE is ultimately cleaved 20 into two bioactive forms, p20 and p10 (3, 40) . Because the amount of processed IL-1β 21 increased in response to PGA, we tested whether PGA treatment can also lead to activation of humoral immune responses (41) . These results suggest that PGA is able to induce an innate 12 immunological reaction in the host and thus it may be useful as a novel adjuvant for cancer 13 immunotherapy as well as for vaccines for infectious diseases. 14 The capsule of B. anthracis is produced as the high-molecular weight capsule (>100 15 kDa) which is first polymerized on the bacterial cell surface in vivo, and then degraded to the 16 lower-molecular weight capsule (<14 kDa) (25) . The lower-molecular weight capsule is 17 released from the bacterial cell surface into the culture medium and is known to act as a decoy 18 to protect bacteria from complement (25) . However, lower-molecular weight PGA was not 19 detected in sera of infected mice, which might be either due to a failure of depolymerization 20 of the high molecular weight form in vivo or due to fast clearance from serum (20) . 21 Although the production of PGA by B. anthracis at each stage of anthrax infection is not 22 thoroughly studied, high level of serum PGA reaching up to 500-1000 µg/ml was observed in 23 the later stage of murine infection in which actively produced virulence factors of B.
24
anthracis stimulate cytokine production (20, 39) . Similar levels of serum PGA were observed in rabbit and nonhuman primate models of pulmonary anthrax (39) . In our experiment, we 1 used PGA concentration up to 100 µg/ml, which might be a five times lower than the on October 24, 2017 by guest
